Current Progress and Future Challenges in the Biochemical Diagnosis and Treatment of Pheochromocytomas and Paragangliomas
- 19 May 2008
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 40 (5), 329-337
- https://doi.org/10.1055/s-2008-1073156
Abstract
Findings from five independent studies - with close to 350 patients with pheochromocytoma and more than 2 500 in whom the tumor was excluded - indicate that measurements of plasma free metanephrines provide an overall diagnostic sensitivity of 98% and specificity of 92%. The recommendation that initial testing for the tumor should always include measurements of either plasma or urinary fractionated metanephrines results from recognition of the high diagnostic sensitivity of measurements of plasma metanephrines. The few patients with pheochromocytoma in whom the test may not yield a positive result include those with very small tumors or microscopic disease and others with tumors that do not produce norepinephrine and epinephrine. Such patients are typically normotensive and do not exhibit symptoms of catecholamine excess. Additional measurements of methoxytyramine can be useful for detecting those tumors that produce only dopamine. Suboptimal diagnostic specificity and difficulties in distinguishing true- from false-positive elevations of plasma metanephrines remain challenges for diagnosis. Improvements in analytical technology (e.g., liquid chromatography with tandem mass spectrometry) and new strategies for follow-up testing provide possible solutions to these problems. The single most important remaining clinical care challenge is the development of effective cures for patients with malignant disease. Current treatments, none of which are truly satisfactory, include chemotherapy and radiopharmaceutical therapy with 131I-labelled m-iodobenzylguanidine or radioactive somatostatin analogues. Improvements in treatment may in the future come from several fronts, but proof of efficacy ideally will require well-coordinated multicenter prospective trials in larger numbers of patients than in previous studies.This publication has 70 references indexed in Scilit:
- Plasma Chromogranin A or Urine Fractionated Metanephrines Follow-Up Testing Improves the Diagnostic Accuracy of Plasma Fractionated Metanephrines for PheochromocytomaJournal of Clinical Endocrinology & Metabolism, 2008
- A Radioiodinated MIBG–Octreotate Conjugate Exhibiting Enhanced Uptake and Retention in SSTR2-Expressing Tumor CellsBioconjugate Chemistry, 2007
- Radiolabeled Phenethylguanidines: Novel Imaging Agents for Cardiac Sympathetic Neurons and Adrenergic TumorsJournal of Medicinal Chemistry, 2007
- A kit method for the high level synthesis of [211At]MABGBioorganic & Medicinal Chemistry, 2007
- Pheochromocytoma: recommendations for clinical practice from the First International SymposiumNature Clinical Practice Endocrinology & Metabolism, 2007
- Management and Treatment of Pheochromocytomas and ParagangliomasAnnals of the New York Academy of Sciences, 2006
- Malignant PheochromocytomaAnnals of the New York Academy of Sciences, 2006
- Malignant pheochromocytoma: current status and initiatives for future progressEndocrine-Related Cancer, 2004
- Effects of slow‐release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytomaClinical Endocrinology, 2002
- Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft modelNuclear Medicine and Biology, 1996